Sartorius Stedim Biotech has partnered with Nanotein Technologies, acquiring a minority stake to support commercialization and joint development of immune cell activation solutions based on Nanotein’s NanoSpark® platform. Through an exclusive distribution agreement, Sartorius will offer Nanotein’s soluble activators designed to enhance T cell and natural killer (NK) cell expansion, addressing critical manufacturing challenges in cell therapy production. The collaboration aims to accelerate innovation in cell and gene therapy development pipelines globally.